{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:10:52Z","timestamp":1760141452442,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ejso.2018.05.019","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T12:40:51Z","timestamp":1526992851000},"page":"1142-1147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Inflammatory breast cancer and chest wall disease: The oncologist perspective"],"prefix":"10.1016","volume":"44","author":[{"given":"Giuseppe","family":"Curigliano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejso.2018.05.019_bib1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/annonc\/mdu121","article-title":"Survival of women with inflammatory breast cancer: a large population-based study","volume":"25","author":"Dawood","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2018.05.019_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3233\/BD-2006-22103","article-title":"Epidemiology of inflammatory breast cancer (IBC)","volume":"22","author":"Anderson","year":"2005","journal-title":"Breast Dis"},{"key":"10.1016\/j.ejso.2018.05.019_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/bcr997","article-title":"Update on inflammatory breast cancer","volume":"7","author":"Lerebours","year":"2005","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejso.2018.05.019_bib4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.6004\/jnccn.2011.0018","article-title":"Inflammatory breast cancer","volume":"9","author":"Dushkin","year":"2011","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.ejso.2018.05.019_bib5","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/cncr.22927","article-title":"Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease","volume":"110","author":"Cristofanilli","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2018.05.019_bib6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ejso.2018.05.019_bib7","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1200\/JCO.2008.21.6630","article-title":"Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer","volume":"27","author":"Gray","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2018.05.019_bib8","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2018.05.019_bib9","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2018.05.019_bib10","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","volume":"10","author":"Brufsky","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2018.05.019_bib11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.2005.03.4645","article-title":"Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer","volume":"24","author":"Wedam","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejso.2018.05.019_bib12","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/sj.onc.1210858","article-title":"Breast cancer metastases are molecularly distinct from their primary tumors","volume":"27","author":"Vecchi","year":"2008","journal-title":"Oncogene"},{"issue":"11 Suppl","key":"10.1016\/j.ejso.2018.05.019_bib13","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/cncr.25175","article-title":"Inflammatory breast cancer in Tunisia: epidemiological and clinical trends","volume":"116","author":"Boussen","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2018.05.019_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3233\/BD-2012-000337","article-title":"Inflammatory breast cancer in north Africa: comparison of clinical and molecular epidemiologic characteristics of patients from Egypt, Tunisia, and Morocco","volume":"33","author":"Soliman","year":"2011","journal-title":"Breast Dis"},{"key":"10.1016\/j.ejso.2018.05.019_bib15","unstructured":"A.S. Soliman, C. Schairer. Considerations in setting up and conducting epidemiologic studies of cancer in middle- and low-income countries: the experience of a case-control study of inflammatory breast cancer in North Africa in the past 10 years."},{"issue":"6","key":"10.1016\/j.ejso.2018.05.019_bib16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/annonc\/mdm060","article-title":"Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer","volume":"18","author":"Cabioglu","year":"2007","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2018.05.019_bib17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semradonc.2009.05.008","article-title":"Inflammatory breast cancer","volume":"19","author":"Woodward","year":"2009","journal-title":"Semin Radiat Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2018.05.019_bib18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nchembio.168","article-title":"In\u00a0vivo effects of a GPR30 antagonist","volume":"5","author":"Dennis","year":"2009","journal-title":"Nat Chem Biol"},{"issue":"3\u20135","key":"10.1016\/j.ejso.2018.05.019_bib19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jsbmb.2011.07.002","article-title":"Identification of a GPER\/GPR30 antagonist with improved estrogen receptor counter selectivity","volume":"127","author":"Dennis","year":"2011","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"issue":"2","key":"10.1016\/j.ejso.2018.05.019_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/bies.950060210","article-title":"Growth factors and their receptors: specific roles in development","volume":"6","author":"Burgess","year":"1987","journal-title":"Bioessays"},{"issue":"9712","key":"10.1016\/j.ejso.2018.05.019_bib21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ejso.2018.05.019_bib22","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1158\/1078-0432.CCR-09-0951","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer","volume":"15","author":"Zhang","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejso.2018.05.019_bib23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"G.N. Hortobagyi the HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine","volume":"14","author":"Ross","year":"2009","journal-title":"Oncol"},{"issue":"14","key":"10.1016\/j.ejso.2018.05.019_bib24","first-page":"4332","article-title":"HER-2\/neu amplification predicts poor survival in node-positive breast cancer","volume":"50","author":"Borg","year":"1990","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.ejso.2018.05.019_bib25","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/cncr.23350","article-title":"Prognostic significance of HER-2 status in women with inflammatory breast cancer","volume":"112","author":"Dawood","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ejso.2018.05.019_bib26","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1093\/annonc\/mdq239","article-title":"Incidence of and survival following brain metastases among women with inflammatory breast cancer","volume":"21","author":"Dawood","year":"2010","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.ejso.2018.05.019_bib27","first-page":"7196","article-title":"The characterization of novel, dual ErbB-2\/EGFR, tyrosine kinase inhibitors: potential therapy for cancer","volume":"61","author":"Rusnak","year":"2001","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.ejso.2018.05.019_bib28","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1200\/JCO.2009.21.8594","article-title":"Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer","volume":"28","author":"Boussen","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2018.05.019_bib29","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2007.13.9949","article-title":"Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy","volume":"26","author":"Johnston","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2018.05.019_bib30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/path.1370","article-title":"Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer","volume":"200","author":"Witton","year":"2003","journal-title":"J\u00a0Pathol"},{"issue":"47","key":"10.1016\/j.ejso.2018.05.019_bib31","doi-asserted-by":"crossref","first-page":"44266","DOI":"10.1074\/jbc.M105428200","article-title":"Identification of a heregulin binding site in HER3 extracellular domain","volume":"276","author":"Singer","year":"2001","journal-title":"J\u00a0Biol Chem"},{"issue":"41","key":"10.1016\/j.ejso.2018.05.019_bib32","doi-asserted-by":"crossref","first-page":"24604","DOI":"10.1074\/jbc.270.41.24604","article-title":"Binding of Neu differentiation factor with the extracellular domain of HER2 and HER3","volume":"270","author":"Horan","year":"1995","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"10.1016\/j.ejso.2018.05.019_bib33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/sj.onc.1206130","article-title":"Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer","volume":"22","author":"Tsai","year":"2003","journal-title":"Oncogene"},{"issue":"21","key":"10.1016\/j.ejso.2018.05.019_bib34","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1093\/jnci\/85.21.1765","article-title":"Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma","volume":"85","author":"Riou","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.ejso.2018.05.019_bib35","first-page":"3857","article-title":"Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer","volume":"8","author":"McCarthy","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"18 Pt. 1","key":"10.1016\/j.ejso.2018.05.019_bib36","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1158\/1078-0432.CCR-04-0202","article-title":"p53 expression as a prognostic marker in inflammatory breast cancer","volume":"10","author":"Gonzalez-Angulo","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejso.2018.05.019_bib37","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1158\/1535-7163.MCT-10-0205","article-title":"Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer","volume":"9","author":"Sakai","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejso.2018.05.019_bib38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/2193-1801-2-497","article-title":"Presence of anaplastic lymphoma kinase in inflammatory breast cancer","volume":"2","author":"Robertson","year":"2013","journal-title":"SpringerPlus"},{"issue":"11","key":"10.1016\/j.ejso.2018.05.019_bib39","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S1470-2045(11)70232-7","article-title":"Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis","volume":"12","author":"Shaw","year":"2011","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2018.05.019_bib40","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1200\/JCO.1992.10.6.1014","article-title":"Inflammatory breast cancer: a review","volume":"10","author":"Jaiyesimi","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2018.05.019_bib41","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/84635","article-title":"VEGF-D promotes the metastatic spread of tumor cells via the lymphatics","volume":"7","author":"Stacker","year":"2001","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ejso.2018.05.019_bib42","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/sj.bjc.6600807","article-title":"Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression","volume":"88","author":"Colpaert","year":"2003","journal-title":"Br J Cancer"},{"issue":"23","key":"10.1016\/j.ejso.2018.05.019_bib43","doi-asserted-by":"crossref","first-page":"7965","DOI":"10.1158\/1078-0432.CCR-04-0063","article-title":"Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification","volume":"10","author":"Van der Auwera","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.ejso.2018.05.019_bib44","doi-asserted-by":"crossref","first-page":"7637","DOI":"10.1158\/1078-0432.CCR-05-1142","article-title":"Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study","volume":"11","author":"Van der Auwera","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejso.2018.05.019_bib45","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/84643","article-title":"Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis","volume":"7","author":"Skobe","year":"2001","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ejso.2018.05.019_bib46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1096\/fasebj.13.1.9","article-title":"Vascular endothelial growth factor (VEGF) and its receptors","volume":"13","author":"Neufeld","year":"1999","journal-title":"FASEB J"},{"key":"10.1016\/j.ejso.2018.05.019_bib47","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1471-2407-12-298","article-title":"Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer","volume":"12","author":"Arias-Pulido","year":"2012","journal-title":"BMC Cancer"},{"issue":"18","key":"10.1016\/j.ejso.2018.05.019_bib48","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1158\/1078-0432.CCR-07-4762","article-title":"Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer","volume":"14","author":"Yang","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejso.2018.05.019_bib49","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(12)70049-9","article-title":"Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study","volume":"13","author":"Pierga","year":"2012","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2018.05.019_bib50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.breast.2015.02.036","article-title":"Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: a randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine","volume":"24","author":"Curigliano","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.ejso.2018.05.019_bib51","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/sj.bjc.6690714","article-title":"First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated infl ammatory breast cancer: toxicity and response (PEGASE 02 trial)","volume":"81","author":"Viens","year":"1999","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1016\/j.ejso.2018.05.019_bib52","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1200\/JCO.2012.44.7912","article-title":"AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent\/metastatic breast cancer","volume":"31","author":"Gianni","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2018.05.019_bib53","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.breast.2013.03.012","article-title":"Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer","volume":"22","author":"Clavarezza","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.ejso.2018.05.019_bib54","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.1158\/1078-0432.CCR-07-0688","article-title":"Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin","volume":"13","author":"Overmoyer","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"2","key":"10.1016\/j.ejso.2018.05.019_bib55","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccr.2011.12.026","article-title":"VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium","volume":"21","author":"Karnezis","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejso.2018.05.019_bib56","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1158\/0008-5472.CAN-05-1843","article-title":"Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2","volume":"66","author":"Roberts","year":"2006","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.ejso.2018.05.019_bib57","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/annonc\/mdt496","article-title":"Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival","volume":"25","author":"Bertucci","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2018.05.019_bib58","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa1111097","article-title":"Bevacizumab added to neoadjuvant chemotherapy for breast cancer","volume":"366","author":"Bear","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ejso.2018.05.019_bib59","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.seminoncol.2010.09.005","article-title":"Immune checkpoint proteins: a new therapeutic paradigm for cancer\u2013preclinical background: CTLA-4 and PD-1 blockade","volume":"37","author":"Weber","year":"2010","journal-title":"Semin Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2018.05.019_bib60","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.955691","article-title":"Consensus guidelines for the detection of immunogenic cell death","volume":"3","author":"Kepp","year":"2014","journal-title":"OncoImmunology"},{"issue":"5","key":"10.1016\/j.ejso.2018.05.019_bib61","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798318310734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798318310734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:25:27Z","timestamp":1760059527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798318310734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0748798318310734"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2018.05.019","relation":{},"ISSN":["0748-7983"],"issn-type":[{"type":"print","value":"0748-7983"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory breast cancer and chest wall disease: The oncologist perspective","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2018.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}